The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro†
Open accessAbstract
Cyclosporin A (CsA) inhibits the in vitro replication of HCV subgenomic replicons. We here report on the potent anti-HCV activity of the non-immunosuppressive cyclosporin DEBIO-025. The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Huh 5-2 cells (luciferase assay) by DEBIO-025 was 0.27 +/- 0.03 microg/mL and for CsA 2.8 +/- 0.4 microg/mL. The concentration that reduced the growth of exponentially proliferating Huh 5-2 cells by 50% was greater than 27 microg/mL for DEBIO-025 and 12 +/- 6 microg/mL for CsA, resulting in a selectivity index of approximately 900 for DEBIO-025 and 40 for CsA. The superior activity of DEBIO-025, as compared with CsA, was corroborated by monitoring HCV RNA levels in Huh 5-2, two other HCV subgenomic replicon-containing cell lines, and by monitoring the luciferase signal and viral antigen production in hepatoma cells that had been infected with an infectious full-length chimeric HCV construct. The combination of interferon alpha 2a with either CsA or DEBIO-025 resulted in an additive to slightly synergistic antiviral activity. DEBIO-025, at concentrations of 0.5 and 1 microg/mL, was able to clear cells from their HCV replicon within three to four passages, whereas treatment with CsA at the same concentrations for seven consecutive passages did not result in clearance of the HCV replicon. In conclusion, DEBIO-025, a compound that is also endowed with potent anti-HIV activity and is well tolerated in animals and humans, may form an attractive new option for the therapy of HCV infections, particularly in HCV/HIV co-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Self-citationProduction of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754
Self-citationComplete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238
Robust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
Blight, K. J., McKeating, J. A., & Rice, C. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.13001-13014.2002 · Cited by 1,193
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cyclosporin A Suppresses Replication of Hepatitis C Virus Genome in Cultured Hepatocytes
Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., & Shimotohno, K. (2003) · Hepatology · doi:10.1053/jhep.2003.50449 · Cited by 510
Cyclophilin B Is a Functional Regulator of Hepatitis C Virus RNA Polymerase
Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y., & Shimotohno, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.05.014 · Cited by 454
Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs
Carroll, S. S., Tomassini, J. E., Bosserman, M., Getty, K., Stahlhut, M. W., Eldrup, A. B., Bhat, B., Hall, D., Simcoe, A. L., LaFemina, R., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210914200 · Cited by 335
Novel Insights into Hepatitis C Virus Replication and Persistence
Bartenschlager, R., Frese, M., & Pietschmann, T. (2004) · Advances in Virus Research · doi:10.1016/s0065-3527(04)63002-8 · Cited by 307
Self-citationIn Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Dunn, C. J., Wagstaff, A. J., Perry, C. M., Plosker, G. L., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161130-00006 · Cited by 276
Specific inhibition of hepatitis C virus replication by cyclosporin A
Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, N., Koyama, T., Kurosaki, M., Maekawa, S., Yamashiro, T., Chen, C.-H., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.080 · Cited by 229
Target Cell Cyclophilin A Modulates Human Immunodeficiency Virus Type 1 Infectivity
Sokolskaja, E., Sayah, D. M., & Luban, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.12800-12808.2004 · Cited by 225
Hatziioannou, T., Perez-Caballero, D., Cowan, S., & Bieniasz, P. D. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.176-183.2005 · Cited by 195
Rosenwirth, B., Billich, A., Datema, R., Donatsch, P., Hammerschmid, F., Harrison, R., Hiestand, P., Jaksche, H., Mayer, P., & Peichl, P. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1763 · Cited by 182
Self-citationBillich, A., Hammerschmid, F., Peichl, P., Wenger, R., Zenke, G., Quesniaux, V, & Rosenwirth, B. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2451-2461.1995 · Cited by 174
Self-citationA replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C
Vrolijk, J. M., Kaul, A., Hansen, B. E., Lohmann, V., Haagmans, B. L., Schalm, S. W., & Bartenschlager, R. (2003) · Journal of Virological Methods · doi:10.1016/s0166-0934(03)00134-4 · Cited by 171
Self-citationBell, A., Wernli, B., & Franklin, R. M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90279-8 · Cited by 126
Steinkasserer, A., Harrison, R., Billich, A., Hammerschmid, F., Werner, G., Wolff, B. H., Peichl, P., Palfi, G. E., Schnitzel, W., & Mlynar, E. (1995) · Journal of Virology · doi:10.1128/jvi.69.2.814-824.1995 · Cited by 110
Clinical consequences of hepatitis C virus infection
Zoulim, F., Chevallier, M., Maynard, M., & TREPO, C. G. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.371 · Cited by 109
Antimalarial activity of cyclosporin A
Thommen-Scott, K. (1981) · Inflammation Research · doi:10.1007/bf01978803 · Cited by 80
Dorfman, T., & Göttlinger, H. G. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5751-5757.1996 · Cited by 80
Chatterji, U., Bobardt, M. D., Stanfield, R. L., Ptak, R. G., Pallansch, L. A., Ward, P., Jones, M., Stoddart, C. A., Scalfaro, P., Dumont, J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506314200 · Cited by 73
Self-citationSynthetic routes to NEtXaa4-cyclosporin A derivatives as potential anti-HIV I drugs
Hubler, F., Rückle, T., Patiny, L., Tshilolo, M., Guichou, J., Mutter, M., & Wenger, R. M. (2000) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)01267-3 · Cited by 41
Mlynar, E., Rosenwirth, B., Steinkasserer, A., Bevec, D., & Billich, A. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-4-825 · Cited by 41
Self-citationPlasmodium vivax: In VitroAntiparasitic Effect of Cyclosporins
Kocken, C. H. M., der Wel, A. V.-V., Rosenwirth, B., et al. (1996) · Experimental Parasitology · doi:10.1006/expr.1996.0132 · Cited by 38
Self-citationAntimalarial effect of cyclosporin-A on murine P. berghei and human P. falciparum.
Biswas, S., Saxena, Q. B., & Upender, M. (1991) · PubMed · Cited by 8
Antimalarial activity of cyclosporins A, C and D.
Uadia, P. O., Ezeamuzie, I. C., Ladan, M., et al. (1994) · PubMed · Cited by 6
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Replication of hepatitis C virus
Moradpour, D., Penin, F., & Rice, C. M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1645 · Cited by 1,336
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Host Factors in Coronavirus Replication
de Wilde, A. H., Snijder, E. J., Kikkert, M., & van Hemert, M. J. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_25 · Cited by 546
Metadata
- Authors
- Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J., Scalfaro, P., Bartenschlager, R., & Neyts, J.
- Venue
- Hepatology
- Published
- 2006-04
- Volume
- 43
- Issue
- 4
- Pages
- 761-770
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2062153657
- Cited by
- 279
- References
- 29
- FWCI
- 17.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.